Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Si Lian Kang in H. pylori eradication therapy
NCT04034641Phase 4Unknown
- Sponsor
- Hangzhou Grand Biologic Pharmaceutical Inc.
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 4 trial of Bifidobacterium tetravaccine in Helicobacter pylori infection, sponsored by Hangzhou Grand Biologic Pharmaceutical Inc.. Status: unknown.
02
Drugs
Bifidobacterium tetravaccine
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04034641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034641.